Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1019)	5/11/2001 9:26:56 AM
From: Biomaven	Read Replies (2) \| Respond to of 3158

Well no sooner had I nicely categorized all possible biotech munches, we get one that doesn't fit any of my categories, even at a stretch. <g> This deal is quite a surprise to me. Smart move by MRK though - I've always liked what RSTA was doing and I own some. These pharma seem determined to somehow make me a shareholder. <g> Peter

To: nigel bates who wrote (1019)	5/11/2001 9:28:20 AM
From: aknahow	Respond to of 3158

A bite out of something else. 05-11-01 07:41:39 AM Schering-Plough up in pre-open trade on merger talk NEW YORK, May 11 (Reuters) - Shares of drug-maker Schering-Plough Corp. (SGP.N) were higher in pre-open trading Friday after a published report revived talk that Merck and Co. Inc. (MRK.N) was looking to acquire the firm. Schering-Plough shares were at $40 on the Instinet electronic broker system, up from a Thursday close at $37.10. The stock hit $43 before easing. Merck was not active. "As a matter of policy, we would not comment on a rumor," said Gregory Reaves, a spokesman for Merck, when asked about the report in Business Week magazine. Schering-Plough officials were not immediately available for comment. REUTERS Sure, not a biotech munch, but still of interest.